Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients

Journal of Clinical Psychopharmacology

Volumn 32, Issue 4, 2012, Pages 574-576

  Lecei, Olivera ^a   Lederbogen, Florian ^a   Gronau, Wolfgang ^a   Scharnholz, Barbara ^a   Terhardt, Johannes ^a   Schilling, Claudia ^a   Gilles, Maria ^a   Kopf, Daniel ^a   Roth, Heinz Juergen ^b   Weber Hamann, Bettina ^a,c   Deuschle, Michael ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b Limbach Laboratory   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CATECHOL 3 O METHYLTRANSFERASE; LORAZEPAM; METHYLTRANSFERASE; MIRTAZAPINE; N ACYLNORADRENALINE; NORADRENALIN; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; VENLAFAXINE; ZOLPIDEM;

ADULT; ANALYSIS OF VARIANCE; CONTROLLED STUDY; DSM-IV; FEMALE; HAMILTON SCALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICROTITER PLATE ASSAY; NORADRENALIN RELEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; URINE VOLUME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; NOREPINEPHRINE;

EID: 84863679775     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825ddf1b     Document Type: Letter

References (20)

1. Lesperance F, Frasure-Smith N, Talajic M, et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105:1049-1053. (Pubitemid 34212612)
2. Carney RM, Freedland KE. Depression, mortality and medical morbidity in patients with coronary heart disease. Biol Psychiatry. 2003;54:241-247. (Pubitemid 37267854)
3. Seeman TE, Singer BH, Rowe JW, et al. Price of adaptationVallostatic load and its health consequences. Arch Intern Med. 1997;157:2259-2268.
4. Reuben DB, Talvi SLA, Rowe JW, et al. High urinary catecholamine excretion predicts mortality and functional decline in high-functioning, community-dwelling older persons: MacArthur studies of successful aging. J Gerontol. 2000;55:M618YM624. (Pubitemid 32010299)
5. Laycock SK, McMurray J, Kane KA, et al. Effects of chronic norepinephrine administration on cardiac function in rats. J Cardiovasc Pharmacol. 1995;26:584-589.
6. Esler M. The sympathetic system and hypertension. Am J Hypertension. 2000;13(6 Pt 2):99SY105S. (Pubitemid 30459894)
7. Grassi G, Arenare F, Quarti-Trevano F, et al. Heart rate, sympathetic cardiovascular influences and the metabolic syndrome. Progr Cardiovasc Disord. 2009;52:31-37.
8. Maes M, Minner B, Suy E, et al. Coexisting dysregulations of both the sympathoadrenal system and hypothalamic-pituitary-adrenal axis in melancholia. J Neural Transm. 1991;85:195-210.
9. Grossman F, Potter WZ. Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. Psychiatry Res. 1999;87:21-27. (Pubitemid 29421695)
10. Hughes JW, Watkins L, Blumenthal JA, et al. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res. 2004;57:353-358. (Pubitemid 39424247)
11. Otte C, Neylan TC, Pipkin SS, et al. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry. 2005;162:2139-2145. (Pubitemid 41598269)
12. Swann AC, Stokes PE, Secunda SK, et al. Depressive mania versus agitated depression: biogenic amine and hypothalamic-pituitary-adrenocortical function. Biol Psychiatry. 1994;35:803-813. (Pubitemid 24165003)
13. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind controlled study. Neuropsychopharmacology. 2003;28:1685-1693. (Pubitemid 41070869)
14. Siepmann T, Ziemssen T, Mueck-Weymann M, et al. The effects of venlafaxine on autonomic functions in healthy volunteers. J Clin Psychopharmacol. 2007;27:687-691. (Pubitemid 351339458)
15. Tulen JH, Bruijn JA, de Man KJ, et al. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). J Clin Psychopharmacol. 1996;16:135-145.
16. Scharnholz B, Weber-Hamann B, Lederbogen F, et al. Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: a randomised open trial. Psychiatry Res. 2010;77:109-113.
17. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591-598.
18. Weber-Hamann B, Gilles M, Schilling C, et al. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol. 2008;28:581-584.
19. Powell LH, Lovallo WR, Matthews KA, et al. Physiologic markers of chronic stress in premenopausal, middle-aged women. Psychosom Res. 2002;64:502-509. (Pubitemid 34556416)
20. Henry DP, Dentino M, Gibbs PS, et al. Vascular compartmentalization of plasma norepinephrine in normal men: the relationships between venous and arterial norepinephrine concentration and the urinary excretion of norepinephrine. J Lab Clin Med. 1979;94:429-437. (Pubitemid 10210124)